Development of a Therapeutic to Treat Anthrax in Humans
$2,139,810N01FY2023AINIH
Hawaii Biotech, Inc., Aiea HI
Investigators
Abstract
To support the advanced development of a promising small molecule antitoxin against Anthrax. The research and development activities to be supported will allow this candidate therapeutic product to progress through the product development pathway, and include preclinical and non-clinical activities, IND regulatory development activities, and Phase I clinical safety assessment.
View original record on NIH RePORTER →